61 questions answered from cited research · Plain language
A 2025 systematic review found new standards for bladder cancer: perioperative durvalumab, enfortumab vedotin plus pembrolizumab, and HER2-targeted disitamab vedotin plus toripalimab.
Read the full answer →Blue light cystoscopy (BLC) detects significantly more bladder cancer lesions than white light cystoscopy (WLC), especially carcinoma in situ (CIS), with higher sensitivity and comparable specificity.
Read the full answer →No. A 2024 study found no detectable bladder cancer cells, mutations, or exosomes in surgical smoke from robot-assisted radical cystectomy.
Read the full answer →Combined cognitive-behavioral sleep intervention and nutritional support improve sleep, reduce inflammation, and may improve 2-year survival after rectal cancer surgery.
Read the full answer →Anastomotic leakage after anterior resection for rectal cancer occurs in about 7-10% of patients, with risk factors including male sex, higher tumor stage, and longer surgery.
Read the full answer →Yes, injecting methylene blue into the inferior mesenteric artery during rectal cancer surgery significantly increases the number of lymph nodes detected and reduces variability among pathologists.
Read the full answer →Yes, preoperative models using MRI and clinical data can accurately predict lateral lymph node metastasis in rectal cancer, with AUCs over 0.88 in recent studies.
Read the full answer →Robotic surgery may reduce urinary retention after rectal cancer surgery, but overall functional and oncological outcomes are similar to laparoscopic surgery.
Read the full answer →Type 2 diabetes is linked to a modestly increased risk of pancreatic cancer, especially in long-standing diabetes with insulin resistance, while new-onset diabetes with weight loss may signal an existing tumor.
Read the full answer →Yes, multiple studies show periodontal disease is linked to a higher risk of pancreatic cancer, especially in middle-aged and older adults.
Read the full answer →The study's genetic risk loci apply to endometrial cancer, not to benign polyps, though shared genetic architecture exists.
Read the full answer →Yes, research shows type 2 diabetes is linked to a higher risk of endometrial cancer, likely due to insulin resistance, chronic inflammation, and hormonal changes.
Read the full answer →Yes, women with inherited gynecologic cancer susceptibility, especially Lynch syndrome, have a significantly increased risk of endometrial cancer.
Read the full answer →Yes, the review indicates that microbiome dysbiosis may contribute to endometrial cancer development through chronic inflammation, altered estrogen metabolism, and immune modulation.
Read the full answer →Yes, AI and digital pathology show promise for improving endometrial cancer diagnosis by analyzing tissue images and molecular data, but they are not yet standard practice.
Read the full answer →Brain metastases in NSCLC are driven by tumor cells exploiting the blood-brain barrier, metabolic reprogramming, immune evasion, and specific molecular pathways like SEC61G and S100A9-ALDH1A1.
Read the full answer →Yes, ovarian cancer diagnoses decreased during the early COVID-19 pandemic years, as shown by a Swiss study that found fewer new cases in 2020 and 2021 compared to 2019.
Read the full answer →Inherited cancer susceptibility, especially BRCA1/2 mutations, expands prevention options to include risk-reducing salpingo-oophorectomy, chemoprevention with oral contraceptives, and enhanced surveillance, though screening alone has limited sensitivity.
Read the full answer →Yes, TP53 and PTEN mutations are found in ovarian cancer samples, with TP53 in 68% and PTEN in 47% of cases in one study.
Read the full answer →Olaparib plus bevacizumab is most effective in HRD-positive ovarian cancer; in HR-proficient tumors, benefit is limited, and resistance, side effects, and cost are key limitations.
Read the full answer →Gut microbial metabolites like short-chain fatty acids protect against colorectal cancer in IBD, while secondary bile acids, TMAO, and hydrogen sulfide promote it.
Read the full answer →Yes, interstitial needles improve target dose coverage in cervical cancer brachytherapy, with studies showing about a 4 Gy increase in high-risk CTV dose without raising organ-at-risk doses.
Read the full answer →Yes, a tandem-ring applicator lowers rectal and sigmoid radiation doses compared to tandem-ovoid in cervical cancer brachytherapy, based on a randomized trial.
Read the full answer →Yes, bowel dose-volume predictors like V30Gy and V40Gy can help estimate your risk of GI toxicity after cervical cancer radiotherapy.
Read the full answer →